Chronic Idiopathic Constipation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
- Transparency Market Research
Constipation can be defined as a condition with decreased stool frequency or issues in passing stool. Reduced or tough stool passage is accompanied by hard lumpy stools, incomplete bowel actions, straining, incomplete evacuation, and necessity for manual elimination of stool. Chronic idiopathic constipation (CIC) can be described as an additional, persistent or extreme continuation of the above-mentioned signs and symptoms. Several times, the cause of chronic idiopathic constipation is not known. Since the cause of constipation is uncertain, it is known as idiopathic constipation. Chronic idiopathic constipation Market is often indicated with more than one symptoms.
Based on drug class, the global chronic idiopathic constipation market can be segmented into emollients, laxatives, chloride channel activators, osmotic products, and others. The laxatives segment is likely to expand at a significant pace during the forecast period. The advantage of a laxative is that it can be generally sold over the counter and it can even be prescribed as the first line of treatment to relieve idiopathic constipation. Based on route of administration, the chronic idiopathic constipation market can be segmented into oral and parenteral. The oral segment is likely to expand at a rapid pace during the forecast period, as patients prefer taking oral drugs as they are convenient, invasive, and require no special training to take drugs. Based on distribution mode, the chronic idiopathic constipation market can be segmented into prescription drugs and over-the-counter drugs. The prescription drugs segment is likely to expand at a significant pace during the forecast period, as patients prefer taking drugs prescribed by the doctor to avoid any possible side-effects. In terms of distribution channel, the chronic idiopathic constipation market can be segmented into hospital pharmacies, retail pharmacies, and online sales. The hospital pharmacies segment is likely to expand at a significant pace during the forecast period, as patients prefer hospital pharmacies to buy drugs due to availability of a variety of drugs to treat CIC in these pharmacies. Additionally, patients have easy access to several medicines prescribed by the doctor. Increasing prevalence of irritable bowel syndrome with constipation (IBS-C), rising use of opioid drugs, and growing geriatric population across the region are factors driving the global chronic idiopathic constipation market. However, low awareness about guidelines for the diagnosis and treatment of idiopathic constipation are likely to hamper chronic idiopathic constipation market in the next few years.
In terms of region, the global chronic idiopathic constipation market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global chronic idiopathic constipation market. The region is projected to hold a significant share of the global chronic idiopathic constipation market during the forecast period, due to increasing prevalence of chronic idiopathic constipation among the geriatric population in the region. Shifting focus of key players in Europe toward specialty constipation medicines is likely to drive of the demand for specialty therapeutic options such as PAMORA’s and GC-C agonists in the region. On the other hand, high prevalence of functional constipation and increasing health care expenditure in Asia Pacific are expected to fuel the chronic idiopathic constipation market in the region during the forecast period. Advancements in drug delivery, increase in per capita income, and availability of generic drugs are likely to augment the chronic idiopathic constipation Market in Middle East & Africa during the forecast period.
Key players operating in the global chronic idiopathic constipation market are GlaxoSmithKline Plc., Bayer AG, Allergan Plc., Ironwood Pharmaceuticals, Inc., Astellas Pharma, Inc., Synergy Pharmaceuticals, Inc., Sanofi S.A., and Pfizer, Inc. among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Have query on this report?Make an Enquiry
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017